Rezolute, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2023, compared with fiscal 2022. Although the request metadata refers to “2022 Q4,” this filing is an annual report for fiscal 2023, not a quarterly filing. Rezolute is a clinical-stage biopharmaceutical company and has no commercial products.
Business context and development programs
- RZ358: Intravenous antibody being developed for congenital hyperinsulinism (HI). The company planned to begin the Phase 3 sunRIZE study outside the U.S. in the fourth quarter of calendar 2023, enrolling participants from 3 months to 45 years; topline results were anticipated in the first half of 2025. The prior Phase 2b RIZE study was described as generally safe and well tolerated and as improving hypoglycemia.
- RZ402: Oral plasma kallikrein inhibitor in a Phase 2 study for diabetic macular edema (DME). The company expected to complete enrollment in 2023 and announce topline results in the first quarter of calendar 2024.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $43.8 million | $32.5 million |
| General and administrative expense | $12.2 million | $9.4 million |
| Total operating expenses / operating loss | $56.0 million | $41.8 million |
| Interest and other income | $4.2 million | $0.1 million |
| Net loss | $51.8 million | $41.1 million |
| Basic loss per share | $1.01 | $2.26 |
| Cash used in operating activities | $44.5 million | $39.6 million |
- R&D expense rose 35%, principally reflecting increased staffing and spending on both clinical programs, including RZ402’s $3.0 million Phase 2 milestone payment to ActiveSite.
- Cash and cash equivalents were $16.0 million at June 30, 2023, versus $150.4 million a year earlier. Marketable debt securities were $102.3 million; working capital was approximately $99.7 million. The portfolio had $0.351 million in net unrealized losses.
- Investing activities used $101.5 million, mainly for purchases of marketable debt securities. Financing activities provided $11.6 million, primarily from the July 2022 private placement. The $15.0 million loan, plus fees, had been repaid in June 2022; the company reported no outstanding borrowing principal at year-end.
- Total liabilities were $7.5 million, including $2.5 million in operating lease liabilities and a $0.4 million embedded derivative liability. There was no meaningful revenue or applicable operating margin.
- Management’s MD&A states available resources were expected to fund planned activities through at least the third quarter of calendar 2025. However, the liquidity note says at least through September 2024. This discrepancy is important to verify.
Material changes, outlook and risks
- The FDA maintained a restriction limiting U.S. RZ358 study participants to age 12 and older and reimposed a dose exposure cap based on historical rat liver findings. The U.S. program remained on clinical hold; the company said the restrictions made U.S. participation in sunRIZE infeasible at that time. It was pursuing additional nonclinical work to address FDA concerns while advancing Phase 3 outside the U.S.
- The company attributed the rat findings to a potentially species-specific effect, citing no comparable liver findings in monkeys at higher exposures or in closely monitored human trials. FDA acceptance of this position is not assured.
- Future development and commercialization depend on clinical outcomes, regulatory approvals, manufacturing and third-party supply, and additional financing. The company expects continuing operating losses and states it will need additional financing for longer-term obligations and operations.
- Potential clinical and regulatory milestone payments include up to $35.0 million to XOMA and $25.0 million to ActiveSite; a $5.0 million XOMA payment was expected upon first-patient dosing in RZ358 Phase 3. Further sales-based and alternative-indication milestones could total $202.5 million, plus royalties, if products are commercialized.
- Other disclosed risks include clinical-trial delays or failure, adverse events, competition, intellectual-property challenges, supply-chain and inflation pressures, securities portfolio interest-rate and credit risk, and potential dilution from outstanding equity awards and warrants. The company reported no pending or threatened lawsuits expected to have a material effect.
- The independent auditor issued an unqualified opinion on the financial statements and reported no critical audit matters. Management stated disclosure controls and internal control over financial reporting were effective at June 30, 2023, and that a previously identified segregation-of-duties material weakness had been remediated. The auditor did not attest to internal-control effectiveness.
Important facts for investors to verify
- Reconcile the liquidity runway disclosures: third quarter of calendar 2025 in MD&A versus September 2024 in the liquidity note.
- Check actual initiation, enrollment and progress of sunRIZE, and any subsequent FDA actions on the U.S. clinical hold, age restriction and dose cap.
- Check RZ402 Phase 2 enrollment, topline results and any changes to its expected development timeline.
- Assess cash burn, marketable securities, investment maturities and financing needs against the stated runway and upcoming $5.0 million XOMA milestone.
- Monitor clinical results, safety findings, regulatory requirements, licensing milestones and potential share dilution from outstanding options and pre-funded warrants.